Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CSL Ltd

CSL.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Large Cap Analyst: HOLD

Last Close

$96.66

▼ -0.74%

Market Cap $46.11B · Vol 1.28M

Key Metrics

P/E Ratio

33.54

FWD: 14.96

Market Cap

$46.11B

Large Cap

Div Yield

3.12%

Semi-annual dividend

EPS Growth

-4.69%

YoY

RSI (14)

79.27

Momentum

Beta

0.51

vs Market

52W High

$193.63

45.55% below

52W Low

$63.73

50.67% above

Volume

1.28M

Avg 1.15M

P/B

3.95

Price-to-book

ROE

17.54%

Return on equity

Free Float

99.97%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, CSL Ltd (CSL.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CSL.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.26%

+11.01%

+40.35%

-9.01%

YTD

-20.94%

-49.46%

-45.10%

-54.12%

Financials & Valuation

TTM · Annual

Total Revenue	$15.56B
Net Income	$3.14B
Revenue Growth (YoY)	-1.78%
Gross Margin	51.93%
Operating Margin	26.38%
Net Profit Margin	20.16%
ROE	17.54%
ROA · ROIC	9.62% · 10.47%

P/E Ratio	33.54
Forward P/E (FY1)	14.96
PEG Ratio	1.91
P/S	4.92
P/B	3.95
P/FCF	29.89
EPS Growth	-4.69%
Outstanding Shares	478.91M

Technical Indicators

50-Day SMA	$84.85
200-Day SMA	$102.13
RSI (14)	79.27
Beta	0.51
52-Week High	$193.63
52-Week Low	$63.73

Volume Today	1.28M
Avg Daily Volume (30D)	1.15M
Relative Volume	1.11x
Volatility (10D)	21.62
Volatility (30D)	32.72
Free Float	99.97%

Analyst Consensus

HOLD

Current Price $96.66

Mean Target $95.66

52W Low$63.73 52W High$193.63

Current

Target

$63.73 $193.63

Current Analyst target

-1.03% downside risk · 16 analysts

Identifiers

ExchangeASX

FIGIBBG001S7YNK1

ISINAU000000CSL8

CountryAustralia

Sub-IndustryBiopharmaceuticals

Earnings DateAug 17, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% BIIB Biogen Inc -0.39% INCY Incyte Corp -0.30%

Company Profile

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.